265 related articles for article (PubMed ID: 26407760)
1. RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Kruszewski AM; Rao G; Tatomir A; Hewes D; Tegla CA; Cudrici CD; Nguyen V; Royal W; Bever CT; Rus V; Rus H
Exp Mol Pathol; 2015 Dec; 99(3):498-505. PubMed ID: 26407760
[TBL] [Abstract][Full Text] [Related]
2. The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.
Tatomir A; Talpos-Caia A; Anselmo F; Kruszewski AM; Boodhoo D; Rus V; Rus H
Immunol Res; 2017 Dec; 65(6):1103-1109. PubMed ID: 29116612
[TBL] [Abstract][Full Text] [Related]
3. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis.
Hewes D; Tatomir A; Kruszewski AM; Rao G; Tegla CA; Ciriello J; Nguyen V; Royal W; Bever C; Rus V; Rus H
Exp Mol Pathol; 2017 Apr; 102(2):191-197. PubMed ID: 28109694
[TBL] [Abstract][Full Text] [Related]
4. Dual role of Response gene to complement-32 in multiple sclerosis.
Tegla CA; Cudrici CD; Azimzadeh P; Singh AK; Trippe R; Khan A; Chen H; Andrian-Albescu M; Royal W; Bever C; Rus V; Rus H
Exp Mol Pathol; 2013 Feb; 94(1):17-28. PubMed ID: 23000427
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Ciriello J; Tatomir A; Hewes D; Boodhoo D; Anselmo F; Rus V; Rus H
Exp Mol Pathol; 2018 Oct; 105(2):175-180. PubMed ID: 30028960
[TBL] [Abstract][Full Text] [Related]
6. IL-27: a potential biomarker for responders to glatiramer acetate therapy.
Mindur JE; Valenzuela RM; Yadav SK; Boppana S; Dhib-Jalbut S; Ito K
J Neuroimmunol; 2017 Mar; 304():21-28. PubMed ID: 27449853
[TBL] [Abstract][Full Text] [Related]
7. SIRT1 is decreased during relapses in patients with multiple sclerosis.
Tegla CA; Azimzadeh P; Andrian-Albescu M; Martin A; Cudrici CD; Trippe R; Sugarman A; Chen H; Boodhoo D; Vlaicu SI; Royal W; Bever C; Rus V; Rus H
Exp Mol Pathol; 2014 Apr; 96(2):139-48. PubMed ID: 24397908
[TBL] [Abstract][Full Text] [Related]
8. JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response.
Anselmo F; Tatomir A; Boodhoo D; Mekala AP; Nguyen V; Rus V; Rus H
Clin Immunol; 2020 Jan; 210():108297. PubMed ID: 31698073
[TBL] [Abstract][Full Text] [Related]
9. B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis.
Tacke S; Braune S; Rovituso DM; Ziemssen T; Lehmann PV; Dikow H; Bergmann A; Kuerten S
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33707177
[TBL] [Abstract][Full Text] [Related]
10. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
11. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients.
Zecca C; Disanto G; Sacco R; Riccitelli GC; Gobbi C
BMC Neurol; 2019 Jul; 19(1):159. PubMed ID: 31299922
[TBL] [Abstract][Full Text] [Related]
12. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
Ziemssen T; Calabrese P; Penner IK; Apfel R
J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
[TBL] [Abstract][Full Text] [Related]
13. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
Valenzuela RM; Kaufman M; Balashov KE; Ito K; Buyske S; Dhib-Jalbut S
J Neuroimmunol; 2016 Nov; 300():59-65. PubMed ID: 27390072
[TBL] [Abstract][Full Text] [Related]
14. The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
Melnikov M; Sharanova S; Sviridova A; Rogovskii V; Murugina N; Nikolaeva A; Dagil Y; Murugin V; Ospelnikova T; Boyko A; Pashenkov M
PLoS One; 2020; 15(10):e0240305. PubMed ID: 33126239
[TBL] [Abstract][Full Text] [Related]
15. 12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
Signoriello E; Iardino P; Casertano S; De Lucia D; Pucciarelli A; Puoti G; Chiosi E; Lus G
J Neuroimmunol; 2020 Nov; 348():577385. PubMed ID: 32927398
[TBL] [Abstract][Full Text] [Related]
16. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T
J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969
[TBL] [Abstract][Full Text] [Related]
17. CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate.
Vališ M; Sobíšek L; Vyšata O; Klímová B; Andrýs C; Vokurková D; Masopust J; Pavelek Z
Cells; 2019 May; 8(5):. PubMed ID: 31096621
[No Abstract] [Full Text] [Related]
18. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers.
Neuhaus O; Köhler W; Then Bergh F; Kristoferitsch W; Faiss J; Rosenkranz T; Reske D; Patejdl R; Hartung HP; Zettl UK
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33800033
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups.
Pavelek Z; Novotny M; Soucek O; Krejsek J; Sobisek L; Sejkorova I; Masopust J; Kuca K; Valis M; Klimova B; Stourac P
Mult Scler Relat Disord; 2021 Aug; 53():103082. PubMed ID: 34166982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]